Status:
NOT_YET_RECRUITING
Sirolimus With corTicOsteroid TheraPy for Rapid rEcurrences of Coronary Unexplained In-stent Restenosis
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborating Sponsors:
Chinese Academy of Medical Sciences, Fuwai Hospital
The First Hospital of Jilin University
Conditions:
In-stent Restenosis Lesion
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD))
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This study aims to evaluate, through a multicenter, prospective, double-blind, randomized, placebo-controlled clinical trial, whether immunosuppressive therapy improves target lesion-related cardiovas...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- Able to understand the trial design and sign an informed consent form
- Patients meeting the RECUR definition
- Satisfactory results from revascularization within the past two weeks
- Receiving standard secondary prevention medication for coronary heart disease with treatment targets achieved
Exclusion
- Pregnant women, individuals known to be allergic to the study drug, those currently participating in other interventional clinical trials, or participants deemed unsuitable for this study based on the investigator's judgment.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT06981845
Start Date
June 1 2025
End Date
June 1 2028
Last Update
May 21 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.